# A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer

> **NCT07497919** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 20 (estimated)

## Conditions studied

- Penile Cancer

## Interventions

- **DRUG:** Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb)

## Key facts

- **NCT ID:** NCT07497919
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2029-05-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07497919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07497919, "A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07497919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*